Skip to main content
. 2019 May 15;10(5):372. doi: 10.3390/genes10050372

Figure 4.

Figure 4

HMGA1 and HMGA2 expression in endometrioid endometrial adenocarcinomas (EEC) from The Cancer Genome Atlas (TCGA) cohort, and their potential as a prognostic biomarker. HMGA1 and HMGA2 gene expression reanalysis in EEC patients comprising TCGA cohort, according to clinicopathological characteristics. (A,E) Tumor staging: HMGA1 and HMGA2 expression was assessed in 139 EEC samples from stage IA, 123 from stage IB, 35 from stage II, 70 from stage III, 14 samples from stage IV and in 20 non-cancerous, tumor-adjacent endometrial tissue samples. (B,F) Histological grade: HMGA1 and HMGA2 expression reanalyzed in 95 well differentiated (G1), 107 moderately differentiated (G2), 179 poorly differentiated (G3) EEC samples and in 20 non-cancerous, tumor-adjacent endometrial tissue samples. (C,D,G,H) Survival analysis. (C,D). Evaluation of the association between the expression of HMGA1 on the 381 EEC patients’ disease-free survival (C) (HR = 1.974, CI = 1.199–3.249, p = 0.00749) and overall survival (D) (HR = 1.930, CI = 1.046–3.562, p = 0.03) by univariate analysis. (G,H) Evaluation of the association between the expression of HMGA2 on the 381 EEC patients’ disease-free survival (G) (HR = 0.5272, CI = 0.2508–1.109, p = 0.889) and overall survival (H) (HR = 1.51, CI = 0.3624–6.217, p = 0.67) by univariate analysis. HMGA1 low expression < 12.92, HMGA1 high expression ≥ 12.92; HMGA2 low expression < 7.68, HMGA2 high expression ≥ 7.68.